Glaukos Corporation (NYSE: GKOS) announced results from a long-term Phase 3 extension study evaluating its Epioxa corneal cross-linking therapy for keratoconus, showing sustained efficacy and safety ...
Three-year data demonstrate sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable ...
As most people are aware, there are two billing components for a corneal cross-linking treatment: the procedure, or T code, ...
Please provide your email address to receive an email when new articles are posted on . Optometrists are often first to diagnose a patient with keratoconus and hold a great responsibility for ...
LAGUNA HILLS, CA, UNITED STATES, July 10, 2026 /EINPresswire.com/ — Harvard Eye Associates is proud to announce the availability of Epioxa HD / Epioxa (“Epioxa ...
SEATTLE — Keeping our vision strong is important throughout life. Conditions like keratoconus, though, can cause vision to decline. “The cornea is important to be clear,” said Dr. Luke Barker of ...
PESHAWAR: Pakistan Institute of Community Ophthalmology at Hayatabad Medical Complex has decided to start the latest corneal procedures to be able to use all sorts of tissues sent by a US-based ...
Glaukos Corporation announced positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results